Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab vs Eculizumab in Naive PNH
NCT02946463Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels and Percentage Of Participants Who Achieved Transfusion Avoidance (TA). Started Dec 2016; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02946463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946463.